-

INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of Eargo, Inc. (EAR) Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Eargo, Inc. (“Eargo” or the “Company”) (NASDAQ: EAR). The investigation concerns whether Eargo has violated the federal securities laws and/or engaged in other unlawful business practices.

On September 22, 2021, after the close of trading, Eargo disclosed that “it is the target of a criminal investigation by the U.S. Department of Justice (the ‘DOJ’) related to insurance reimbursement claims the Company has submitted on behalf of its customers covered by federal employee health plans.” The Company admitted that “[a]s previously disclosed, the Company has been the subject of an ongoing claims audit by an insurance company that is the Company’s largest third-party payor. The Company has been informed by the insurance company that the DOJ is now the principal contact related to the subject matter of the audit.” Eargo also added that it “is withdrawing its financial guidance for the fiscal year ending December 31, 2021.” On this news, the Company’s share price declined by $14.81 per share, or approximately 68.3%, from $21.67 per share to close at $6.86 per share on September 23, 2021.

If you purchased or otherwise acquired Eargo securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:EAR

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

ADMA INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving ADMA Biologics, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On March 24, 2026, Culper Research published a report on ADMA alleging “Channel Stuffing, an Undisclosed Related Par...

TBRG INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving TruBridge, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of TruBridge, Inc. (“TruBridge” or the “Company”) (NASDAQ:TBRG) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On March 16, 2026, TruBridge disclosed that it would be unable to timely file its 2025 Annual Report because “errors...

INVESTOR ALERT: Securities Class Action Filed Against Aldeyra Therapeutics – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Aldeyra Therapeutics (“Aldeyra” or the “Company”) (NASDAQ:ALDX) securities during the period of November 3, 2023 through March 16, 2026, inclusive (“the Class Period”). If you suffered a loss on your Aldeyra investments, you have until May 29, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitte...
Back to Newsroom